Venclexta® (venetoclax) – Expanded indication
June 8, 2018 - Genentech announced the FDA approval of Venclexta (venetoclax), for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
Top